Pamiparib - BeiGene

Drug Profile

Pamiparib - BeiGene

Alternative Names: BeiGene-290; BGB-290; PARPi - BeiGene

Latest Information Update: 20 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BeiGene
  • Developer BeiGene; Merck Serono
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Poly(ADP-ribose) polymerase 1 inhibitors; Poly(ADP-ribose) polymerase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Ovarian cancer
  • Phase I/II Glioblastoma; Solid tumours
  • Phase I Breast cancer; Fallopian tube cancer; Peritoneal cancer

Most Recent Events

  • 16 Apr 2018 Safety and efficacy data of phase I trial of pamiparib presented at American Association for Cancer Research Annual Meeting 2018 (AACR-2018)
  • 28 Feb 2018 BeiGene plans a global phase III trial for Gastric cancer in 2018
  • 09 Feb 2018 BeiGene plans a phase III trial for Gastric Cancer (First-line therapy; Late-stage disease) in USA , (NCT03427814)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top